All In Biotech

Drug Trial Radar · NCT07473700

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Nov 21, 2027

Study completion Dec 11, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.

Conditions

  • Hypertension, Pulmonary
  • Lung Diseases, Interstitial

Interventions

  • TX000045Drug

    Subcutaneous Injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change from Baseline in PVR up to 16 WeeksTime frame: Baseline up to 16 weeks
  2. Number of Participants with Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 21 weeks
  3. Number of Participants with Clinically Significant Changes from Baseline in Safety Laboratory Assessments, 12-Lead Electrocardiogram (ECG) Assessments and Vital Sign AssessmentsTime frame: Baseline up to 21 weeks

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Phoenix

    Phoenix, Arizona · Recruiting

  • San Francisco

    San Francisco, California · Recruiting

  • Idaho

    Boise, Idaho · Not yet recruiting

  • Allen Park

    Allen Park, Michigan · Recruiting

  • Krakow

    Krakow, Poland · Not yet recruiting

  • Lublin

    Lublin, Poland · Not yet recruiting

  • Wroclaw

    Wroclaw, Poland · Recruiting

  • Bucharest

    Bucharest, Romania · Recruiting

  • Belgrade

    Belgrade, Serbia · Recruiting

  • Sremska Kamenica

    Kamenitz, Serbia · Recruiting

  • Niš

    Niš, Serbia · Recruiting

  • Gyeonggi-Do

    Gyeonggi-do, South Korea · Recruiting

  • Seoul

    Seoul, South Korea · Recruiting

  • Barcelona

    Barcelona, Spain · Not yet recruiting

  • Madrid

    Madrid, Spain · Recruiting

  • Santander

    Santander, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.